Skip to main content
. 2019 Jan 30;9(4):1047–1065. doi: 10.7150/thno.29820

Figure 1.

Figure 1

Synthesis and characterization of Pt(IV) NP-cRGD. (A) Synthetic route used to prepare Pt(IV) NP-cRGD. (B) 1H NMR spectra of the DSPE-PEG1k-Pt(IV) in CDCl3. The characteristic peaks are pointed out and magnified (right). (C) 1H NMR spectra of Pt(IV) NP-cRGD in DMSO-d6. The characteristic peaks are pointed out and magnified (right). (D) Size distribution of Pt(IV) NP-cRGD before (red) and after (black) US exposure. (E) Storage stability of Pt(IV) NPs and Pt(IV) NP-cRGD at 4 °C, 25 °C and 37 °C. (F) Serum stability of Pt(IV) NPs and Pt(IV) NP-cRGD. Serum-induced aggregation assay was monitored based on turbidity at the indicated time. (G) TEM image of Pt(IV) NP-cRGD before (a1,a2) and after US treatment at 10 s (b1,b2) and 60 s (c1,c2). (H) Pt release profiles from Pt(IV) NP-cRGD, GSH: glutathione. Data are presented as the mean ± SD of three independent experiments. Statistical significance in (H) was calculated by two-way ANOVA with Sidak's post hoc test. *P < 0.05, **P < 0.01, ***P < 0.005, NS indicates P > 0.05.